Vipul C. Chitalia, M.D., Ph.D.

Associate Professor, Medicine

Vipul Chitalia
617.414.1773
650 Albany St Evans Biomed Research Ctr

Biography

Our laboratory focuses on the role of post-translational modifications of proteins, especially polyubiquitnation of the key mediators of vascular pathologies in diseases such as cancer and renal failure. While these diseases are discrete, several fundamental biological processes remain similar. Through a highly collaborative network, our laboratory harnesses the power of various cellular and molecular biological tools, relevant animal models (zebrafish and mice), computational methods and machine-learning techniques and strives to validate these findings and hypotheses in humanized models or human samples from large data bases, which highlights the translational nature of our approach.

A. Vascular diseases in kidney failure: Close to 20 million Americans or 10% of US population suffer from the chronic kidney disease (CKD). Among plethora of cardiovascular manifestations, CKD patients are particularly at high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation) in CKD patients. This area of CKD management warrants urgent investigation due to lack of risk predictors and CKD-specific therapeutic targets.
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity, and hence called uremic solutes/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes, which inhibits the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding into the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis) and to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.
Thrombosis being a dynamic and the multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM and established a Thrombosis and Hemostasis ARC, which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis. http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/

B. Angiogenesis: Angiogenesis, a process of generation of novel blood vessel is fundamental during the development and in various diseases such as cancer. Wnt signaling, a highly conserved oncogenic pathway is critical in angiogenesis. Beta catenin is the prime mediator of Wnt activation. Focusing on the ubiquitination and proteasomal degradation of beta catenin, our previous work had described Jade-1, as an E3 ligases of wild-type beta catenin. Our recent efforts have specifically focused on c-Cbl as an E3 ligase for the mutant beta catenin and for the transcriptionally active beta catenin in the nucleus. These two species of beta catenin, once considered resistant to degradation are effectively downregulated by c-Cbl. Thus, c-Cbl is a unique E3 ligase of tumorigenic beta catenin, which is involved in several cancers including colorectal cancer pathogenesis. Leveraging the cancer animal models and human cancer samples including machine learning based quantitative histology! techniques, our group investigates the colorectal cancer pathogenesis to gain deeper understanding of the role of E3 ligases of beta catenin E3 ligases in various cancers.

Other Positions

  • Member, Whitaker Cardiovascular Institute, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences

Education

  • Seth G.S. Medical College, MD
  • Lokmanya Tilak Medical College and Hospital, MBBS
  • Seth G.S. Medical College, DM

Publications

  • Published on 11/1/2021

    Walker JA, Richards S, Whelan SA, Yoo SB, Russell TL, Arinze N, Lotfollahzadeh S, Napoleon MA, Belghasem M, Lee N, Dember LM, Ravid K, Chitalia VC. Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD. J Am Soc Nephrol. 2021 Nov; 32(11):2834-2850. PMID: 34716244.

    Read at: PubMed
  • Published on 9/9/2021

    Chen DY, Khan N, Close BJ, Goel RK, Blum B, Tavares AH, Kenney D, Conway HL, Ewoldt JK, Chitalia VC, Crossland NA, Chen CS, Kotton DN, Baker SC, Fuchs SY, Connor JH, Douam F, Emili A, Saeed M. SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. J Virol. 2021 09 09; 95(19):e0086221. PMID: 34260266.

    Read at: PubMed
  • Published on 6/30/2021

    Amraei R, Yin W, Napoleon MA, Suder EL, Berrigan J, Zhao Q, Olejnik J, Chandler KB, Xia C, Feldman J, Hauser BM, Caradonna TM, Schmidt AG, Gummuluru S, Mühlberger E, Chitalia V, Costello CE, Rahimi N. CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2. ACS Cent Sci. 2021 Jul 28; 7(7):1156-1165. PMID: 34341769.

    Read at: PubMed
  • Published on 6/27/2021

    Verma A, Chitalia VC, Waikar SS, Kolachalama VB. Machine Learning Applications in Nephrology: A Bibliometric Analysis Comparing Kidney Studies to Other Medicine Subspecialities. Kidney Med. 2021 Sep-Oct; 3(5):762-767. PMID: 34693256.

    Read at: PubMed
  • Published on 6/4/2021

    Kamel MH, Mahmoud H, Zhen A, Liu J, Bielick CG, Mostaghim A, Lin N, Chitalia V, Ilori T, Waikar SS, Upadhyay A. End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts. PLoS One. 2021; 16(6):e0252679. PMID: 34086775.

    Read at: PubMed
  • Published on 5/23/2021

    Zheng Y, Cassol CA, Jung S, Veerapaneni D, Chitalia VC, Ren KYM, Bellur SS, Boor P, Barisoni LM, Waikar SS, Betke M, Kolachalama VB. Deep-Learning-Driven Quantification of Interstitial Fibrosis in Digitized Kidney Biopsies. Am J Pathol. 2021 08; 191(8):1442-1453. PMID: 34033750.

    Read at: PubMed
  • Published on 3/23/2021

    Ravid JD, Kamel MH, Chitalia VC. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease. Nat Rev Nephrol. 2021 06; 17(6):402-416. PMID: 33758363.

    Read at: PubMed
  • Published on 10/31/2020

    Kamel MH, Yin W, Zavaro C, Francis JM, Chitalia VC. Hyperthrombotic Milieu in COVID-19 Patients. Cells. 2020 10 31; 9(11). PMID: 33142844.

    Read at: PubMed
  • Published on 10/29/2020

    De La Cena KOC, Ho RX, Amraei R, Woolf N, Tashjian JY, Zhao Q, Richards S, Walker J, Huang J, Chitalia VC, Rahimi N. Transmembrane and Immunoglobulin Domain Containing 1, a Putative Tumor Suppressor, Induces G2/M Cell Cycle Checkpoint Arrest in Colon Cancer Cells. Am J Pathol. 2021 01; 191(1):157-167. PMID: 33129760.

    Read at: PubMed
  • Published on 10/28/2020

    Chen DY, Khan N, Close BJ, Goel RK, Blum B, Tavares AH, Kenney D, Conway HL, Ewoldt JK, Kapell S, Chitalia VC, Crossland NA, Chen CS, Kotton DN, Baker SC, Connor JH, Douam F, Emili A, Saeed M. SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway. bioRxiv. 2020 Oct 28. PMID: 33140044.

    Read at: PubMed

View 79 more publications: View full profile at BUMC

View all profiles